Cargando…
1538. Who Will Benefit From Therapeutic Drug Monitoring of Ganciclovir?
BACKGROUND: Oral valganciclovir and intravenous ganciclovir are used for prophylaxis, treatment, and pre-emptive treatment of cytomegalovirus and human herpesvirus 6. It is important to estimate the exposure to these antivirals, as deviating levels can cause adverse events or induce acquired drug re...
Autores principales: | Martson, Anne-Grete, Sturkenboom, Marieke G G, Berger, Stefan P, Damman, Kevin, Verschuuren, Erik A M, Blokzijl, Hans, Bakker, Martijn, Span, Lambert F R, Touw, Daan J, van der Werf, Tjip S, Knoester, Marjolein, Alffenaar, Jan-Willem C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809420/ http://dx.doi.org/10.1093/ofid/ofz360.1402 |
Ejemplares similares
-
Ganciclovir therapeutic drug monitoring in transplant recipients
por: Märtson, Anne-Grete, et al.
Publicado: (2021) -
Ganciclovir Therapeutic Drug Monitoring: A Case Series
por: Märtson, Anne-Grete, et al.
Publicado: (2019) -
Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads
por: Märtson, Anne-Grete, et al.
Publicado: (2021) -
Therapeutic Drug Monitoring of Ganciclovir: Where Are We?
por: Märtson, Anne-Grete, et al.
Publicado: (2022) -
Exploring failure of antimicrobial prophylaxis and pre-emptive therapy for transplant recipients: a systematic review
por: Märtson, Anne-Grete, et al.
Publicado: (2020)